ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib mesylate is a small-molecule TKi created to target c-ABL and BCR-ABL, employed for the therapy of chronic myeloid leukemia and gastrointestinal stromal tumors.